CSL Limited (CSLLY)
OTCMKTS · Delayed Price · Currency is USD
86.28
-1.33 (-1.52%)
Aug 7, 2025, 12:16 PM EDT
CSL Limited Employees
CSL Limited had 32,698 employees as of June 30, 2024. The number of employees increased by 633 or 1.97% compared to the previous year.
Employees
32,698
Change (1Y)
633
Growth (1Y)
1.97%
Revenue / Employee
$465,778
Profits / Employee
$84,042
Market Cap
83.57B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 32,698 | 633 | 1.97% |
| Jun 30, 2023 | 32,065 | 2,065 | 6.88% |
| Jun 30, 2022 | 30,000 | 5,000 | 20.00% |
| Jun 30, 2021 | 25,000 | -2,000 | -7.41% |
| Jun 30, 2020 | 27,000 | 1,969 | 7.87% |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Tian'an Technology Group | 8 |
| Elite Pharmaceuticals | 68 |
| Glass House Brands | 374 |
| Spruce Biosciences | 21 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| American Oncology Network | 1,914 |
| Silence Therapeutics | 116 |
CSL Limited News
- 7 weeks ago - U.S. Food and Drug Administration Approves CSL's ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All Patients From the Start - PRNewsWire
- 2 months ago - England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy - PRNewsWire
- 3 months ago - CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy - PRNewsWire
- 4 months ago - CSL Limited: Divergent Outlook For Its 2 Key Businesses - Seeking Alpha
- 6 months ago - CSL Receives Approval in Japan for ANDEMBRY® (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-Activated Factor XII Monoclonal Antibody for the Prevention of Acute Attacks of Hereditary Angioedema (HAE) - PRNewsWire
- 6 months ago - European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine - PRNewsWire
- 6 months ago - European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) - PRNewsWire
- 6 months ago - Half Year 2025 CSL Ltd Earnings Presentation Transcript - GuruFocus